Abbott Laboratories

Strong Financial Performance: Abbott delivered a solid performance in Q4 2024, achieving organic sales growth of 10% (excluding COVID testing), with adjusted earnings per share increasing by 13% versus the prior year. For the full year 2024, sales growth was 9.5% and operating cash flow reached $8.5 billion.

2025 Guidance: The company forecasts organic sales growth of 7.5% to 8.5% and adjusted earnings per share of $5.05 to $5.25 in 2025, indicating robust double-digit growth at the midpoint. This outlook reflects strong momentum and improved margins while returning $5 billion to shareholders through dividends and share repurchases.

Margin Expansion: Abbott expects to achieve an adjusted gross margin profile of approximately 57% in 2025, representing an 80 basis point improvement from the previous year. This increase is attributed to ongoing gross margin expansion efforts and operational leverage, despite challenges from foreign exchange and a higher tax rate.